Photophysical characterization, biocompatibility and anticancer studies of green fabricated copper doped zirconium dioxide nanoparticles derived from Clitoria ternatea Authors: Kishore Parthasarathy, Vignesh Palani, J Nijasritha, Varshana Prabhu, Koyeli Girigoswami Published: 2026 ABSTRACT AbstractIn an attempt to make the best out of waste, we have utilised shade-dried flower aqueous extract, Clitorea ternatea, to synthesise nanoparticles and apply them to the biomedical field. Cancer treatment has faced many obstacles due to resistance to chemotherapeutic drugs and radio-resistance. Alternative palliative therapy can pave the way for this limitation. Copper-doped zirconia nanoparticles were synthesised in this present study, using Clitorea ternatea flower aqueous extract, and were characterised using UV–vis spectrophotometry, dynamic light scattering, zeta potential analysis, XRD, FTIR, SEM, and EDX. The size of the nanoparticles, as revealed by SEM, was in the range of 87–150 nm, and the zeta potential was − 19 mV, showing their nano size and moderate stability, respectively. Further, the biocompatibility was assessed using in vitro cell viability and haemolysis assay. The nanoparticles were found to be biocompatible up to a dose of 50 μg/mL. These nanoparticles have also shown antioxidant activity as well as cervical cancer cell-killing activity. The IC 50 for SiHa cells was found to be 23.8 μg/mL. The outcome of this study indicated that Cu–ZrO2–CT nanoparticles can be a promising candidate to be used along with conventional therapy to address cervical cancer. However, further studies are warranted using other cancer cell lines, as well as tumour models in animals.Supplementary InformationThe online version contains supplementary material available at 10.1186/s11671-026-04704-5.Keywords: Clitorea ternatea, Copper doping, Zirconia nanoparticles, Zebrafish embryos, Cervical cancer, Healthcare Introduction Good health and well-being fall under UN SDG-03 and are the need of the hour. Cancer remains one of the most formidable challenges in modern medicine, characterised by uncontrolled cell growth and the potential to metastasise throughout the body [1]. Its prevalence underscores the urgent need for innovative therapeutic strategies, especially considering the limitations of current treatments such as chemotherapy and radiotherapy [2]. Approximately 80–90% of cancer-related mortality is attributed to chemotherapy resistance, with many tumours developing resistance to drugs like cisplatin, doxorubicin, and paclitaxel, leading to relapse and poor outcomes. Chemoresistance limits treatment effectiveness across cancers. Radiotherapy shows benefit in only a fraction of cases, partly due to radioresistance, causing recurrence and poor prognosis. About 50% of patients receive radiotherapy, but effectiveness varies widely among tumour types, as resistance impairs control [3, 4]. These approaches often inflict collateral damage on healthy tissues, leading to severe side effects and reduced quality of life for patients [5–7]. Recent advancements in nanotechnology offer promising avenues for improving cancer treatment [8–10]. Nanoparticles, due to their small size and unique physicochemical properties, can be tailored to target cancer cells specifically while sparing healthy tissue [11]. Despite significant progress in cancer treatment, challenges persist, necessitating the development of new therapeutic strategies. Resistance to chemotherapy drugs, for instance, remains a major impediment, driven by genetic mutations and adaptive mechanisms within cancer cells. Moreover, the toxicity of conventional treatments often limits their efficacy and patient compliance, highlighting the critical need for alternative approaches. Natural products [12, 13] and marine algae-based scaffolds [14] have also shown some promising effects in inhibiting cancer cell proliferation. The development of metal and metal oxide nanoparticles has revolutionised the field of biomedical science [15], offering new opportunities in drug delivery [16, 17], imaging [18], biosensing [19], theranostics [20], photodynamic therapy [21], wastewater remediation [22], solar cell applications [23] and antimicrobial therapy [24–26]. Among them, zirconium dioxide (ZrO₂) nanoparticles have attracted significant attention due to their excellent biocompatibility, mechanical strength, and stability [27, 28]. When doped with transition metals like copper (Cu), ZrO₂ nanoparticles exhibit enhanced biological and photophysical properties, including improved antimicrobial efficacy [29] and reactive oxygen species (ROS) generation—features that are highly desirable for medical applications such as wound healing, targeted drug delivery, and cancer therapy [30]. Copper doping improves the efficacy of cervical cancer cell killing via apoptosis, which was recently evidenced by researchers using a copper-based coordination polymer against cervical cancer cells [31]. The incorporation of Cu into the ZrO₂ lattice not only modifies the bandgap but also imparts functional properties [32] that are critical in biomedical contexts, including antibacterial [29, 33, 34] and antioxidant activity. In recent years, the focus has shifted toward green synthesis approaches that utilise plant-based materials to reduce the environmental impact and toxicity associated with conventional chemical synthesis [35–40]. Clitoria ternatea, commonly known as butterfly pea, is a medicinal plant rich in phenolic compounds, flavonoids, and anthocyanins [41–45]—natural agents capable of reducing metal ions and stabilising nanoparticle formation [46, 47]. These bioactive compounds not only facilitate nanoparticle synthesis but may also enhance the therapeutic potential of the resulting nanomaterials. The flower is an agro-waste that can be used for the synthesis of a nanoparticle, making it the best out of waste. A previous study has reported the synthesis of ZnO nanoparticles using egg shell waste and Citrus aurantium fruit peel extract for multiple biomedical and agricultural applications, respectively [48, 49] In this study, Cu-doped ZrO₂ nanoparticles were synthesised using an aqueous extract of Clitoria ternatea flowers by the precipitation method. The study aimed to introduce an environmentally friendly nanostructure that can effectively kill cervical cancer cells at a low dose treatment, without damaging the normal cells. The shade-dried flower extract was prepared through a combined process of ultrasonication and magnetic stirring, followed by filtration using Whatman filter paper to ensure purity. The synthesised nanoparticles were subjected to photophysical characterisation to evaluate their structural, optical, and functional properties. Techniques such as UV–vis absorption spectroscopy, dynamic light scattering (DLS), zeta potential, X-ray diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), scanning electron microscopy (SEM), and elemental analysis (EDX) were employed to understand their complete characteristics. The synthesised nanoparticles were assessed using the MTT assay to determine cytotoxicity on mammalian cell lines, the haemolysis assay to evaluate their interaction with red blood cells, and the zebrafish (Danio rerio) in vivo assay to monitor systemic toxicity and developmental effects. Finally, the anticancer activity was estimated using the SiHa cervical cancer cell line via MTT assay. This work underscores the promise of plant-mediated synthesis in generating multifunctional nanomaterials for advanced medical applications, paving the way for safer, more effective therapeutic platforms. Materials and methods Materials Zirconium (IV) propoxide was purchased from Sigma-Aldrich, copper(II) nitrate (Cu(NO₃)₂), nitric acid (HNO₃), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 3-(4,5-di methyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), Dulbecco's Modified Eagle Medium (DMEM), antibiotics and antimycotic solution, and all reagents for phytochemical tests and E3 medium were of analytical grade and procured from HiMedia Pvt. Ltd., India. Ethanol (95% purity) and carbinol (methanol) were procured from E Merck, India. Foetal bovine serum was ordered from Gibco, USA, and the cell lines, 3T3-L1 and SiHa, were received from NCCS, Pune, India. Clitoria ternatea flowers, dried and powdered form was purchased from Amazon India Ltd. Double-distilled water was used for all experiments. Whatman No.1 filter paper was used for filtration. Preparation of Clitoria ternatea aqueous extract Dried Clitoria ternatea flower powder (0.5 g) was mixed with 200 mL of distilled water. The mixture was subjected to ultrasonication using a bath sonicator at 50 Hz for 15 min, repeated four times to enhance extraction at room temperature (25 °C) and physiological pH of 7.2. The solution was then magnetically stirred at 500 RPM for 1 h at a temperature of 70–75 °C. After complete extraction, the mixture was filtered using Whatman No.1 filter paper to obtain a clear aqueous extract. The final concentration of the plant extract was 0.25% w/v, and the yield was calculated to be approximately 30%. Phytochemical screening and GC–MS analysis Phytochemical analysis of the Clitoria ternatea flower extract was performed to identify the bioactive compounds responsible for the reduction and capping of nanoparticles. The following tests were carried out according to Garg et al. [50]- Carbohydrates: Molisch’s test, Alkaloids: Dragendorff’s test, Wagner’s test, Mayer’s test, Glycosides: Legal’s test, Bornträger’s test, Saponins: Frothing test, Flavonoids: Ferric chloride test, Alkaline reagent test, Tannins: Ferric chloride test, Proteins and Amino Acids: Biuret and Ninhydrin tests. Gas Chromatography–Mass Spectrometry (GC–MS) analysis was performed to identify the secondary metabolites present in the aqueous extract of Clitoria ternatea. For conducting GC–MS analysis, the aqueous extract was completely dried in a rotary evaporator and reconstituted using methanol and subjected to GC–MS analysis using the methodology as described before [11, 51]. Briefly, the analysis was conducted using an Agilent Technologies 7890B gas chromatograph coupled with a 5977B mass selective detector. A total of 3 µL of the extract was diluted with methanol prior to injection. The diluted sample was injected manually in split mode into a DB-5 ms capillary column (30 m × 250 µm × 0.25 µm film thickness). Helium was used as the carrier gas at a constant flow rate of 1.0 mL/min. The injection port temperature was maintained at 280 °C. The initial oven temperature was set to 60 °C and programmed to increase linearly to 310 °C with a 3-min hold at the final temperature. The total run time was 29 min. Compounds were identified based on their retention time, fragmentation pattern, and comparison with spectral data in the NIST (National Institute of Standards and Technology) mass spectral library using Automated Mass Spectral Deconvolution and Identification System (AMDIS) software. This allowed for the identification of bioactive phytochemicals present in the extract, which may play a role in the reduction and stabilisation of nanoparticles during green synthesis. Synthesis of Cu-Doped ZrO₂ nanoparticles (Cu–ZrO2–CT) The nanoparticles were synthesised by a modified precipitation method [52]. A precursor solution was prepared by mixing 3.075 mL of zirconium propoxide and 0.151 g of copper (II) nitrate in 18.75 mL of ethanol. The pH of the solution was adjusted to 4.0 using dilute HNO₃, and the mixture was stirred at 500 RPM for 30 min under aluminium foil cover to avoid photodegradation. After 30 min, 1.485 mL of the prepared Clitoria ternatea extract and 6.25 mL of ethanol were added dropwise to the precursor solution with continuous stirring for a further two hours, until visible precipitation occurred. The resulting precipitate was washed twice with ethanol by centrifugation at 5000 RPM for 10 min each to remove impurities. The washed precipitate was then transferred to a porcelain crucible and calcined in a hot plate at 300 °C for 3 h with occasional stirring using a stainless-steel spatula. The resulting solid product was ground into a fine powder using a mortar and pestle and stored in airtight containers for further characterisation. Scheme 1 shows the process of synthesis of Cu–ZrO2–CT nanoparticles. The steps of synthesis of Cu–ZrO2–CT nanoparticles Characterisation techniques implemented Various physicochemical tools were applied for the characterisation of Cu–ZrO2–CT nanoparticles according to our previous study [9–11]. For all solution-based characterisations (UV–vis spectrophotometry, zeta potential, and dynamic light scattering), 0.1 g of synthesised nanoparticle powder was dispersed in 100 µL of DMSO and diluted with 10 mL of normal saline (0.9% NaCl in double-distilled water). The suspension was sonicated for 15 min using a bath sonicator to ensure uniform dispersion. The sonicated sample was analysed using a Malvern Zetasizer Nano ZS instrument to determine the hydrodynamic particle size and zeta potential. These measurements provided insight into particle stability and dispersion behaviour in aqueous systems. The same diluted nanoparticle dispersion was subjected to UV–visible spectrophotometry to assess optical absorption properties and confirm the formation of nanoparticles using a JASCO V-730 spectrophotometer. Powdered samples were used for SEM, EDX, XRD, and FTIR analysis. Morphological analysis of the synthesised nanoparticles was conducted using SEM (Thermo Fisher, FEI QUANTA 250 FEG). The powdered sample was coated with a conductive layer of Gold and Palladium alloy to prevent charging and analysed to determine particle shape and surface texture. EDX was used for the elemental analysis of the sample. Crystallographic properties were assessed by X-ray diffraction (XRD) using a Unique D8 diffractometer. The powdered sample was subjected to XRD to identify phase purity, crystallite size, and structural parameters of Cu–ZrO2–CT nanoparticles. To identify functional groups and confirm interactions between plant biomolecules and nanoparticles, FTIR analysis was performed. A KBr pellet of the nanoparticle sample was prepared and scanned in the range of 400–4000 cm⁻1 using Bruker Alpha FTIR. Antioxidant activity and biocompatibility assessment DPPH radical scavenging activity was employed to assess the antioxidant activity of the as-synthesised Cu–ZrO2–CT nanoparticles. The method followed was essentially as described by Gulcin 2023 [53]. Different dilutions of the as-synthesised Cu–ZrO2–CT nanoparticles in methanol were taken in triplicate test tubes and added with the DPPH agent (0.1 mM) in methanol and incubated for 30 min in the dark. The positive control taken was ascorbic acid, and the blank taken was only the DPPH reagent in methanol (without any sample), and the absorbance was measured at 517 nm. The amount of free radical activity was calculated as follows: Where, (O.D.) blank is the O.D. of only DPPH in methanol; (O.D.) sample is the O.D. of the tubes containing Cu–ZrO2–CT nanoparticles or ascorbic acid. In vitro biocompatibility was evaluated using MTT assay with normal fibroblast cell line, 3T3-L1, cultured in DMEM containing 10% FBS and 1% antibiotic–antimycotic solution. Briefly, 24 h-grown cells were trypsinised and cultured in a 96-well plate with a cell density of 104 cells per well, and allowed to grow for a further 24 h in a CO2 incubator with a humidified atmosphere. Treatment with different doses of Cu–ZrO2–CT nanoparticles (suspended in PBS and duly filtered using a syringe filter under sterile conditions) was done, and incubated for 24 h. MTT reagent was added to the wells (100 μL), and dark incubation was done for 4 h for the formazan crystal formation, which was dissolved in DMSO, followed by absorbance measurement at 570 nm using a Tecan plate reader. The cell viability percentage was then calculated using the formula used before [11]. Haemolysis assay was performed using human blood after due approval from the Institutional Ethics Committee (005/07/2025/IEC/SMCH), Saveetha Medical College and Hospitals, Thandalam, Chennai, India. Informed consent was obtained from a Male volunteer, 21 years of age, to draw three mL of venous blood. After drawing the blood, it was stored in an EDTA-coated vacutainer. The experiments were conducted in accordance with the Declaration of Helsinki. The haemolysis assay was performed using the procedure followed earlier [8, 54]. In vivo, we observed the developmental stages and hatchability of zebrafish embryos after treatment with different doses of as-synthesised Cu–ZrO2–CT nanoparticles. To conduct zebrafish embryo studies, approval was obtained from the Institutional Animal Ethics Committee (IAEC approval No. SU/CLAR/RD/19/2025), Saveetha Medical College and Hospital, SIMATS. The ARRIVE guidelines were followed to conduct the study. The embryos at 8 hpf were purchased from Tarun Fish Farm, 2/32C, East Mada Street, Manimangalam- 601301. Chennai, Tamil Nadu. Reg. No: FWCS_80, Perungalathur. The 8 h post fertilisation (hpf) embryos were procured and washed gently using distilled water using a Pasteur pipette in a glass Petri plate to remove the dirt and slime present above the eggs. Then, the selection of healthy embryos was performed under a light microscope, and 30 embryos per dose were placed in a 24-well plate filled with E3 medium. For each dose, embryos were kept in triplicate. Treatment was done with 10 μg/mL, 25 μg/mL, and 50 μg/mL of Cu–ZrO2–CT nanoparticles. Every day, the embryos were watched for any developmental abnormalities and hatching. Embryo images were captured with a mobile phone camera, and cumulative hatchability was calculated. Any delayed hatching was also noted in comparison to untreated control embryos. Anticancer activity The cancer cell killing capacity of the as-synthesised Cu–ZrO2–CT nanoparticles was assessed using the cervical cancer cell line, SiHa. MTT assay was performed as described in Sect. 2.6, and the inverted microscopic images, 24 h after treatment, were also documented. Statistical analysis Statistical significance compared with the untreated control was assessed using a paired Student’s t-test. All analyses were conducted in triplicate. Jamovi (free version) was used for statistical analysis, and p < 0.05 was considered statistically significant. Results Clitoria ternatea aqueous extract composition The preliminary phytochemical screening of Clitoria ternatea flower extract revealed the presence of several bioactive compounds, which act as reducing and stabilising agents during nanoparticle synthesis. Qualitative tests showed that alkaloids, glycosides, and coumarins were present in the extract (Fig. S1a). These phytochemicals, especially the alkaloids, are known to donate electrons and facilitate the reduction of metal ions, while simultaneously stabilising the formed nanoparticles by capping their surfaces. Gas Chromatography–Mass Spectrometry (GC–MS) analysis of Clitoria ternatea flower extract was performed to identify the phytoconstituents responsible for the reduction and stabilisation of Cu-doped ZrO₂ nanoparticles. The chromatogram revealed five major peaks corresponding to different bioactive compounds (Fig. S1b), with retention times ranging from 26.811 to 29.680 min. The chromatograms of these compounds are depicted in Fig. S1c–g representing 3-Chloropropane-1,2-diol, bis(tert-butyldimethylsilyl) ether; 10-Hydroxydecanoic acid; Thiourea, N-(2-methoxyphenyl)-N'-(2-propenyl)-; 8-Methoxy-3-oxo-2,4-dihydro-1,4- benzoxazine-6-carbaldehyde; and Adipic acid, dec-4-enyl isobutyl ester, respectively. The identified compounds included the following compounds (Table 1), which are known for their antioxidant, anti-inflammatory, and reducing properties. Table 1The chemical components of Clitoria ternatea extract as revealed by GC–MS analysisPeak #Compound nameChemical formulaMolecular weightRetention time (min)% Abundance13-Chloropropane-1,2-diol, bis(tert-butyldimethylsilyl) etherC15H35ClO2Si233826.81122.77210-Hydroxydecanoic acidC10H20O318827.28417.963Thiourea, N-(2-methoxyphenyl)-N'-(2-propenyl)-C11H14N2OS22228.47126.1148-Methoxy-3-oxo-2,4-dihydro-1,4-benzoxazine-6-carbaldehydeC10H9NO420729.58517.045Adipic acid, dec-4-enyl isobutyl esterC20H36O434029.68016.12 The chemical components of Clitoria ternatea extract as revealed by GC–MS analysis Characterisation of the Cu–ZrO2–CT nanoparticles UV visible data suggested multiple absorption peaks in the UV region (236 nm, 269 nm, and 298 nm) (Fig. 1a). This can be attributed to multiple sizes of the nanoparticles present as well as the presence of doped and undoped ZrO2 nanoparticles. However, the results are in corroboration with a previously published article, where the absorption peak of copper-doped ZrO2 nanoparticles was found to be 260 nm [55]. The band gap was found to be 2.36 eV (Fig. 1b), which is in agreement with the band gap of a semiconductor [56]. The surface charge of the synthesised Cu-doped ZrO₂ nanoparticles was evaluated using zeta potential analysis. The measured zeta potential was found to be − 19 mV, indicating a moderate colloidal stability of the nanoparticles. A value above ± 25 mV is generally considered stable due to sufficient electrostatic repulsion [57–59], and the obtained result suggests that the nanoparticles possess moderate stability in aqueous suspension. The stability and reactivity of nanomaterials are strongly influenced by thermodynamic parameters such as Gibbs free energy, entropy, and enthalpy changes. Due to their high surface-to-volume ratio, nanoparticles possess elevated surface energy, which makes them significantly more reactive than their bulk counterparts. As a result, they are more susceptible to aggregation, dissolution, and undesirable phase transformations under varying environmental conditions. Without proper stabilization through surface coating or functionalization, nanomaterials may gradually lose their structural integrity and functional effectiveness over time [60]. However, moderate stability may limit the efficacy of the nanoparticle in eliciting its biological activity due to partial aggregation. The moderate zeta potential also reflects the presence of phytochemicals from Clitoria ternatea extract acting as capping agents, contributing to stabilisation of the nanoparticle surface. a The absorption spectrum, b band gap, c hydrodynamic diameter, d FTIR, e XRD, f SEM and g EDAX of the as-synthesised Cu–ZrO2–CT nanoparticles The hydrodynamic particle size distribution was determined by DLS (Fig. 1c). The average particle size was recorded as 228 nm, with a polydispersity index (PDI) of 0.42. A lower PDI (< 0.5) indicates a uniform distribution, while higher values suggest some degree of aggregation [61]. The SEM micrographs (Fig. 1f) revealed that the Cu–ZrO2–CT nanoparticles were predominantly spherical in shape with a particle size distribution of approximately 87–150 nm. The hydrodynamic diameter, however was 228 nm, which is a little higher than the diameter obtained by SEM analysis. Dynamic light scattering is based on the movement of a particle in its solvent along with a surrounding layer of water molecules [62]. Hence, the size is detected higher than the actual size considering the water layer as a part of the particle. This is the reason why we get the SEM dimensions lower than those of the DLS data. The morphology indicated a relatively uniform distribution, and slight agglomeration was observed, which may be attributed to the natural phytochemical capping agents from the plant extract. The nanoscale dimension confirmed the successful synthesis of Cu-doped ZrO₂ nanoparticles via the green route. Moreover, the EDX analysis (Fig. 1g) clearly showed the presence of Zr and O, confirming the proper synthesis. EDAX spectrum confirmed the elemental composition of the synthesised nanoparticles. Strong characteristic peaks for Zr, O, and Cu were observed, validating the doping of copper into the zirconium oxide lattice. Minor peaks corresponding to Au were also detected, which could be attributed to the conducting coating done over the sample before performing the SEM analysis. The elemental atomic weight percentage analysis revealed Zr = 21.1%, O = 75.6%, Cu = 1.7%, confirming successful incorporation of copper dopant into the ZrO₂ matrix. These findings confirm that the Cu–ZrO2–CT nanoparticles are nanoscale in dimension with a relatively stable dispersion. The semi-crystalline nature of the synthesised Cu-doped ZrO2 nanoparticles was confirmed using XRD (Fig. 1e). The diffractogram displayed distinct peaks at 2θ values of 32 and 53 degrees, which correspond to the characteristic planes of the tetragonal and cubic phases of ZrO2 nanoparticles. Previous study has reported that after calcinating at 600 °C, the cubic phase of ZrO2 dominated with high intensity peaks present at 32 and 53 degrees. Whereas the same study revealed that these two peaks are present for the tetragonal structure of ZrO2 also after mechanical milling [63]. Thus, we can assume that our nanoparticle was a mixture of cubic and tetragonal structures. However, the background noise of the XRD indicated an amorphous structure mixed with a crystalline structure. The limitation of lower crystallinity (6.8% crystalline and 93.2% amorphous) can be attributed to the low calcinating temperature in our study (300 ºC). FTIR spectra were recorded to identify the functional groups responsible for the reduction and stabilisation of the nanoparticles (Fig. 1d). The spectrum showed prominent absorption bands at 3287 cm⁻1 representing O–H stretching, 1542 cm−1 denoting C=O stretching, 1640 cm−1 for C–O stretching, and 1337 cm−1 for C–C stretching. Strong bands around 614 cm−1 and 827 cm−1 were attributed to Zr–O vibrations, confirming the formation of ZrO2 [55, 64]. In vitro and in vivo biocompatibility The assessment of biocompatibility becomes essential when we apply any nanostructure for biomedical applications. In the present study, we have estimated the biocompatibility both in vitro and in vivo. Normal fibroblast cell line 3T3-L1 was chosen for in vitro studies (Fig. 2a), which demonstrated that up to a dose of 320 μg/mL, there was not much toxicity induced by the Cu–ZrO2–CT nanoparticles (94% cells were alive). The inverted microscopic images of the cells also showed a healthy morphology for doses 25 μg/mL and 50 μg/mL, comparable to the untreated control cells. On the other hand, the hemocompatibility of these nanoparticles was also within the safety limit of 5%. We could see (Fig. 2b) that at low dose (10 μg/mL), the haemolysis percentage was 3.75 ± 0.7%, whereas for the high dose, 50 μg/mL, the percentage of haemolysis was only 1.5 ± 0.15%. It is known that up to a haemolysis percentage of 5% is rendered safe for human use [54, 65, 66]. There was a decrease in haemolysis percentage at the highest dose, which can be attributed to aggregation of the nanoparticles. Reports exist that a bell-shaped haemolysis curve has been found for silver nanoparticles [67]. Thus, our synthesised nanoparticles were safe for use up to a dose of 50 μg/mL. a The MTT assay results and inverted microscopic images of 3T3-L1 cells, b Haemolysis percentage and images of the tubes used for haemolysis assay, c Microscopic images of zebrafish embryos at different hpf, and d Cumulative hatchability of the embryos after treatment with different doses of Cu–ZrO2–CT nanoparticles The in vivo data using zebrafish embryos suggested that the Cu–ZrO2–CT nanoparticles did not induce any developmental abnormality or delayed hatching in the developing embryos. Figure 2c showed that all the embryos were healthy and growing in a similar fashion, like the untreated control embryos. The cumulative hatchability graph (Fig. 2d) showed that nearly 85% embryos hatched after exposure to 50 μg/mL of the nanoparticles, indicating good biocompatibility. These complementary assays provide a holistic view of the biological impact of the nanomaterials and their safety profile. The results aim to establish the potential of Clitoria ternatea-mediated Cu-doped ZrO2 nanoparticles as safe, multifunctional nanomaterials for translational applications in nanomedicine. Antioxidant and anticancer activity of Cu–ZrO2–CT nanoparticles It has been reported earlier that anticancer agents also possess antioxidant activity [68, 69]. To explore this fact, we wanted to measure the free radical scavenging activity of as-synthesised Cu–ZrO2–CT nanoparticles. Figure 3c shows that our nanoparticle exhibited a moderate antioxidant activity, which was, however, lower than that of ascorbic acid at the same dose. From these results, we can speculate that our nanoparticles could act as a free radical scavenger, possibly due to the phytochemicals present during the green synthesis, thereby causing less cellular damage to the benign cells. It is known that metals can cause oxidative stress by Fenton’s reaction, but the balance between ROS generation and antioxidant effect offered by the phytochemicals can cause a balance between the oxidant and antioxidant [70]. In our synthesised nanoparticle, the antioxidant production was higher than the oxidant production, leading to high ROS scavenging activity. a Typical snapshots of SiHa cells observed under an inverted microscope for untreated and after exposure to 25 μg/mL and 50 μg/mL of Cu–ZrO2–CT nanoparticles. b The MTT assay data show the percentage of cell growth inhibition after treatment with different doses of Cu–ZrO2–CT nanoparticles. c The DPPH radical scavenging activity of the nanoparticles after exposure to 10 μg/mL, 20 μg/mL, 30 μg/mL, 40 μg/mL, and 50 μg/mL of Cu–ZrO2–CT nanoparticles and ascorbic acid. (***p < 0.001, compared to untreated control) The anticancer activity was explored using SiHa cells. The inverted microscopic images showed that the cell density was lower after exposure to 50 μg/mL of Cu–ZrO2–CT nanoparticles. There was a dose-dependent cell killing observed, 24 h after exposure to these nanoparticles, and the IC 50 was found to be 23.80 μg/mL (Fig. 3b). In the present study, we have utilised Clitorea ternatea flower extract to synthesize Cu doped ZrO2 nanoparticles. The phytochemical screening of the extract confirmed the presence of alkaloids, glycosides, and coumarins, which are widely reported to possess anticancer, antimicrobial, and anti-inflammatory activities. Their occurrence within the formulation suggests that the bioactive nature of the particles may be attributed, at least in part, to these compounds. Moreover, the GC–MS data also revealed many active lead molecules present in the extract that can contribute as a capping and reducing agent. In a recent study, Clitoria ternatea concentrated aqueous extract (CTE) was characterized by LC–HRMS, showing the various bioactive components. The presence of delphinidin derivatives, cyanidin-3-(p-coumaroyl) glucose, kaempferol 3-(6′-p-coumaroyl)-rutinoside, and kaempferol-rhamnosyl-malonyl-glucoside indicated its rich phytochemical reserve having a predominance of Cyanidin-3-(p-coumaroyl) glucose [71]. These phytochemicals may make a major contribution to the pharmacological activity of CT, and can also act as reducing and capping agents during nanoparticle synthesis. The primary role of doping in zirconia is to stabilise its tetragonal or cubic crystal phases at room temperature. This stabilisation occurs because dopant atoms introduce lattice distortions within the zirconia structure, which helps maintain the high-temperature tetragonal or cubic forms even under ambient conditions. Increasing the dopant concentration enhances this stabilisation effect [72]. Since the tetragonal phase of zirconia has a lower surface energy compared to the monoclinic phase, nanoparticles below a certain critical size tend to remain in the tetragonal form at room temperature [73–76]. This critical size is approximately 30 nm when elastic energy is considered, and about 10 nm if it is neglected [77]. Moreover, studies indicate that the cubic phase can also persist at room temperature when zirconia is subjected to low-temperature calcination or when very fine crystallites are formed, smaller than those that typically yield the tetragonal phase. Although monoclinic zirconia is thermodynamically the most stable phase at room temperature due to its lower free energy, reducing particle size allows the stabilisation of the higher-symmetry tetragonal and cubic phases [78]. Garvie [75] proposed that crystal structures with higher symmetry possess lower surface energies, which explains why increasing dopant concentration further promotes the stability of these phases. Previous reports demonstrated that Yittria or Yittrium oxide is very suitable for doping zirconia since it adds a perfect defect in the crystal, reducing the size enormously [79]. Copper doping has also demonstrated a size reduction in our previous studies [52]. Specifically, Cu incorporation into the ZrO2 lattice introduces defect states and oxygen vacancies due to the difference in ionic radius and valence state between Cu ions and Zr4⁺ ions. These defect levels create intermediate energy states within the band structure, resulting in a reduction of the effective band gap [80, 81]. The narrowed band gap facilitates enhanced electron excitation and suppresses electron–hole recombination, thereby improving charge transfer efficiency. Furthermore, the increased oxygen vacancies and surface defects generated by Cu doping promote ROS formation through surface redox reactions. Cu ions can also participate in Cu2⁺/Cu⁺ redox cycling, which enhances the production of hydroxyl radicals and superoxide species [82]. The elevated ROS generation induces oxidative stress in bacterial and/or cancer cells, leading to membrane damage, protein denaturation, DNA disruption, and ultimately higher cytotoxic activity. Thus, the enhanced cytotoxicity observed for Cu-doped zirconia nanoparticles can be attributed to the combined effects of band gap narrowing, increased oxygen vacancy concentration, improved charge separation, and amplified ROS generation. Furthermore, the SEM-EDAX analysis revealed zirconium, oxygen, and trace copper, all of which were the components of the nanoparticle, indicating the incorporation of Cu in ZrO2. The spherical morphology and nanoscale size range (87–150 nm) are particularly advantageous for biomedical use, as smaller particles typically exhibit a larger surface area, allowing for more efficient drug loading and enhanced cellular uptake. The zeta potential value (− 19 mV) indicates moderate colloidal stability, which, while not optimal for long-term storage, may be suitable for short-term therapeutic delivery systems. Collectively, these characteristics highlight the potential of the formulation to act as a multifunctional nanoplatform for drug delivery and disease management. Additionally, the advantage of being biocompatible was also evidenced both in vitro and in vivo. The nanoparticles also exhibited antioxidant activity, and we could observe that up to a dose of 50 μg/mL, the Cu-ZrO2 nanoparticles can be used safely. Further, the cervical cancer cell killing effect was also documented, showing an IC 50 value (23.8 μg/mL) much lower than the highest safety dose. ROS are highly reactive oxygen-derived molecules formed as natural byproducts of cellular metabolism. Under normal physiological conditions, ROS play essential roles in cell signalling and immune defence. However, when there is an imbalance between ROS production and antioxidant systems, oxidative stress results, damaging various macromolecules such as proteins, lipids, and DNA. This damage can trigger various forms of oxidative cell death, including apoptosis, ferroptosis, necroptosis, paraptosis, parthanatos, pyroptosis, and oxeiptosis, each characterized by its distinct molecular mechanisms. Understanding oxidative cell death pathways becomes crucial for developing therapeutic strategies aimed at preventing cancer initiation and treating established malignancies [83]. In cancer biology, ROS plays a major role as signalling molecules, promoting proliferation, angiogenesis, and metastasis at moderate levels, while inducing cytotoxic damage when they exceed the cell’s antioxidant capacity. To adapt to persistent oxidative stress, cancer cells rely on an enhanced antioxidant network, primarily regulated by the Nrf2 pathway, glutathione (GSH), and thioredoxin (Trx) systems. These mechanisms preserve redox balance and support oncogenic signalling, partly through oxidative inhibition of tumour suppressors such as PTEN, thereby activating the PI3K/AKT/mTOR pathway. Exploiting this dependence on altered redox homeostasis has become a promising therapeutic approach. Pro-oxidant strategies aim to disrupt this balance and induce cancer cell death, with agents such as high-dose vitamin C and arsenic trioxide (ATO) demonstrating selective anticancer effects [84]. Thus, selective anticancer effect is possible by our synthesized nanoparticles due to the redox paradox. Silver nanoparticles green-synthesised using Anethum graveolens extract, Glycyrrhiza glabra L leaf extract, and Phoenix dactylifera seed ethanolic extract have shown promising effects on colon cancer, T-cell leukaemia, and mammary gland carcinoma, respectively [85–87]. Freshly harvested groundnut shells and Pandanus amaryllifolius Roxb. leaf extract were used for silver nanoparticle synthesis, which have been reported to inhibit the proliferation of lung cancer cell lines and breast cancer cell lines, respectively [88, 89]. Green-synthesised gold nanoparticles have been reported to inhibit cancer cell line growth for a spectrum of cancer cell lines, namely, human oesophageal squamous cell carcinoma (KYSE-270), adenocarcinoma of the gastroesophageal junction (ESO26), human Caucasian oesophageal carcinoma (OE33), and distal oesophageal adenocarcinoma (FLO-1) [90]. Lens culinaris seed aqueous extract conjugated gold nanoparticles have been reported to inhibit acute myeloid leukaemia cell proliferation [91]. Fe3O4/Pectin/Au nanocomposites have been reported to show good anticancer activity against three cancer cell lines for adenocarcinoma of human lungs-PC-14, LC-2/ad and HLC-1, in which PC-14 showed the lowest IC50 value [92]. Iron nanoparticles have shown promising contributions for chemotherapeutic drug design [93], whereas Camellia sinensis leaf extract-mediated Cu2O has shown anti-ovarian cancer effect [94]. The IC50 value of L-histidine-capped silver nanoparticles and chitosan-stabilised biogenic silver nanoparticles against SiHa cells was found to be 18.25 ± 0.36 µg/mL and 2.86 ± 0.319 µg/mL, respectively [95, 96]. It is well known that AgNPs are more effective in killing cancer cells compared to other metal and metal oxide nanoparticles. Thus, we can summarise that cancer cells can be killed using these nanoparticles without causing harm to the normal cells. These results corroborate our finding that Cu–ZrO2–CT nanoparticles can selectively kill the cancer cells without affecting the normal cells. However, further experiments are necessary to see the effect in other cancer cell lines and animal models. Study limitations Despite promising findings, the present study has certain limitations. The biological evaluation was restricted to in vitro assays, and the anticancer efficacy was assessed using only a single cervical cancer cell line (SiHa), which limits broader generalisation across different cancer types. Detailed mechanistic insights into nanoparticle-induced cytotoxicity, such as apoptosis pathways, ROS generation, cell cycle arrest, membrane potential analysis, and gene expression changes, were not explored. Additionally, long-term stability, biodistribution, batch-to batch variability, and potential toxicity under physiological conditions were not evaluated. The absence of in vivo animal tumour models further constrains translational relevance. Therefore, comprehensive in vivo studies and multi-cell line analyses are required to validate clinical applicability. Conclusion The present study demonstrates that the nanoscale formulation possesses favourable phytochemical, elemental, and morphological attributes. The presence of bioactive secondary metabolites alongside biocompatible metals supports its pharmacological relevance, while the nanoscale size and spherical morphology further enhance its therapeutic applicability. These combined features suggest that the formulation may serve as a novel candidate for potential anticancer interventions. Overall, the findings provide a preliminary foundation for biomedical applications of this formulation, especially for killing cervical cancer cells in vitro. However, further studies involving in vitro and in vivo assays in other cancer types are essential to validate its efficacy, safety, and stability under physiological conditions. Long-term evaluations of colloidal stability and controlled drug release behaviour will be particularly important to ensure its clinical translation. Supplementary Information Supplementary Material 1. Acknowledgements The authors are grateful to Saveetha Medical College and Hospitals, SIMATS, Thandalam, Chennai-602105, India, for providing them with the infrastructure and facilities to conduct the study. Author contributions K.P., V.Pa., N.J., V.P., K.G.: Methodology, investigation, data curation, experimental design, writing the first draft. K.G.: Supervision, analysis, data visualisation, resources, and finalising the draft. All the authors have read the final draft and given consent to communicate the article. Funding No funding was received for this study. Data availability All the data has been included in the manuscript. If needed with proper justification, the raw data can be obtained from the corresponding author. Declarations Ethics approval and consent to participate Haemolysis assay was performed using human blood after due approval from the Institutional Ethics Committee (005/07/2025/IEC/SMCH), Saveetha Medical College and Hospitals, Thandalam, Chennai, India. Informed consent was obtained from a Male volunteer, 21 years of age, to draw three mL of venous blood, and the experiments were conducted using the Declaration of Helsinki. To conduct zebrafish embryo studies, approval was obtained from the Institutional Animal Ethics Committee (IAEC approval No. SU/CLAR/RD/19/2025), Saveetha Medical College and Hospital, SIMATS. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All the data has been included in the manuscript. If needed with proper justification, the raw data can be obtained from the corresponding author.